Safety and efficacy of ledipasvir/sofosbuvir in post-kidney transplant patients with chronic hepatitis C virus infection

Trial Profile

Safety and efficacy of ledipasvir/sofosbuvir in post-kidney transplant patients with chronic hepatitis C virus infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Feb 2017 Results (n=32) assessing safety and efficacy of Ledipasvir/sofosbuvir in post-kidney transplant patients and in subgroups of patients (GFR of 30 to 60 ml/min/1.73m2; n=12 and HIV coinfected; n=6), published in the Clinical Transplantation
    • 01 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top